<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111444</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-SH-GC-II-010</org_study_id>
    <nct_id>NCT05111444</nct_id>
  </id_info>
  <brief_title>Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</brief_title>
  <official_title>Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of Camrelizumab plus pyrotinib in&#xD;
      combination with chemotherapy in patients with HER2-positive gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>[ Time Frame: Up to approximately 2 years ]</time_frame>
    <description>Objective response rate assessed at 18 weeks after enrollment，that is about 6 cycles of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) per RECIST 1.1 assessed by BICR</measure>
    <time_frame>[ Time Frame: Up to approximately 2 years ]</time_frame>
    <description>The time from the beginning of treatment to the progression or death of the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>[ Time Frame: Up to approximately 2 years ]</time_frame>
    <description>The time from the beginning of treatment to the death of the patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Gastric Neoplasms</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Camrelizumab (200 mg) will be administered intravenously [IV] on day 1 of each 3-week cycle. Pyrotinib (320 mg) will be administered orally once daily [QD] on every 21 days. Chemotherapy will either be XELOX, SOX or TS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>200 mg on Day 1 of each 3-week cycle as an IV infusion</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>320mg as continuous oral once daily on every 21 days</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): &lt;1.25 m^2 BSA =40 mg, 1.25 to &lt;1.5 m^2 BSA=50 mg, ≥1.5 m^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen</description>
    <arm_group_label>Camrelizumab+Pyrotinib + Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. Histologically or cytologically confirmed diagnosis of locally advanced unresectable&#xD;
             or metastatic HER2 positive gastric or GEJ adenocarcinoma.&#xD;
&#xD;
          3. Patients have not received systemic treatment in the past but had disease progression&#xD;
             more than 6 months after receiving neoadjuvant therapy or the last of adjuvant therapy&#xD;
             could be enrolled or failure of first-line therapy or completion of (new) adjuvant&#xD;
             therapy to disease recurrence less than 6 months.&#xD;
&#xD;
          4. HER2-positive defined as either immunohistochemistry (IHC) 3+ or IHC 2+ in combination&#xD;
             with fluorescent in-situ hybridization (FISH+ is defined as HER2:CEP17 ratio≥2.0), as&#xD;
             assessed by central review on primary or metastatic tumor.&#xD;
&#xD;
          5. ECOG performance status 0-1.&#xD;
&#xD;
          6. At least one measurable lesion exists as defined by RECIST 1.1 .&#xD;
&#xD;
          7. Life expectancy of more than 12 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to Camrelizumab, pyrotinib and study chemotherapy agents and/or to&#xD;
             any components.&#xD;
&#xD;
          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with&#xD;
             an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.,&#xD;
             cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, Cluster of&#xD;
             Differentiation 137 [CD137]).&#xD;
&#xD;
          3. Has an active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          4. Has a known history of Human Immunodeficiency Virus (HIV) or active hepatitis B and C&#xD;
             virus infection.&#xD;
&#xD;
          5. Has had major surgery within 28 days prior to randomization, or anticipation of the&#xD;
             need for major surgery during the course of study treatment.&#xD;
&#xD;
          6. Subjects who can not interrupt the using of the drugs that may cause QT prolongation&#xD;
             during study.&#xD;
&#xD;
          7. Evidence or history of coagulation disorders such as a grade ≥ 3 (CTC-AE) bleeding&#xD;
             event.&#xD;
&#xD;
          8. Known history of psychotropic substance abuse or drug use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhe Zhang, PHD</last_name>
    <phone>8621-64175590</phone>
    <email>zhangzhe2010fduscc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>270 Dongan Road, Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

